Scientists identify potential therapeutic target for HER2-driven breast cancer

Posted: 11 January 2018 | | No comments yet

Researchers have made a unique discovery about the role of the MED1 protein in breast cancer formation, showing it to be a promising therapeutic target worthy of future study.

triple negative breast cancer protein

Scientists at the University of Cincinnati College of Medicine identified for the first time that the oestrogen receptor-binding protein MED1 (often expressed at abnormally high levels in breast cancer cells) is a critical mediator of HER2-driven breast cancer.

These findings have the potential to lead to better, more effective treatments for aggressive and treatment-resistant breast cancer.

“Breast cancer remains one of the most common cancers and is one of the leading causes of death for women in the U.S.,” says Xiaoting Zhang, PhD, Associate Professor in the Department of Cancer Biology at the UC College of Medicine, member of the Cincinnati Cancer Center and the UC Cancer Institute who led this study. “Studies have divided breast cancer into several subtypes based on gene expression of oestrogen receptor, progesterone receptor and/or HER2. MED1 is an oestrogen receptor coactivator that has been shown to play important roles in oestrogen receptor-dependent functions in both mammary gland development and breast cancer.

Initial link has been made

“Interestingly, the MED1 gene is located very close to and amplified together with HER2 in the gene, and the MED1 protein levels are highly linked to HER2-positive breast cancer. Additionally, we’ve found that HER2 can activate MED1, and MED1 functions as a key ‘crosstalk’ point between the HER2 and oestrogen receptor pathway in the treatment resistance of HER2 and oestrogen receptor double positive breast cancer. However, the role and underlying molecular functions of MED1 in HER2-driven breast cancer development and spread is still poorly understood.”

Zhang says in this study, researchers generated animal models with the HER2 cancer gene and the mutation of MED1 to evaluate the protein’s role in breast cancer progression and spread.

“The oestrogen receptor specifically binds the MED1 protein in the regions known as the LxxLL motifs. We found that mutating MED1 in the LxxLL motifs disrupted its interaction with the oestrogen receptor and significantly delayed tumour growth, spread and cancer stem-like cell formation in this model,” Zhang says.

“This is the first evidence indicating that MED1 and its LxxLL motifs play a critical role in breast cancer formation, metastasis and cancer stem cell formation.

“This is also the first time a gene co-amplified with HER2 has been shown to play a role in HER2-driven cancer formation. Further investigations looking at the mechanisms underlying MED1 functions revealed that it acted directly to regulate oestrogen signalling through the downstream IGF-1 pathway, a key pathway known to play critical roles in breast cancer. Importantly, human breast cancer patient samples showed a strong correlation between MED1 and IGF-1 protein levels, further supporting the potential of MED1 and its LxxLL motifs as therapeutic targets.

“With these findings and our previously published study showing a tissue-specific role for MED1, we can now conduct further studies on MED1 as a disease-selective therapeutic target. Our team is currently using an RNA nanotechnology-based approach to select RNA aptamers (RNA molecules that bind to a specific target molecule) to specifically target MED1 LxxLL motifs to disrupt the MED1/oestrogen receptor interactions to achieve this.”

Leave a Reply

Your email address will not be published. Required fields are marked *